Gene Therapy Slows Huntington’s Disease in Early Trial

Delve into the various impacts of Huntington disease through engaging visual medical insights and expert discussions

Key Takeaways

  • A high-dose of AMT-130 slowed Huntington’s disease progression by 75% over 36 months

  • Most side effects were related to surgery and resolved, researchers said

  • If approved, this would be the first genetic therapy for Huntington’s disease

Originally published on healthday.com, part of the BLOX Digital Content Exchange.